Skip to main content

Table 3 Survival in accordance with the genetic alterations found in the study. Values are expressed in mean (confidence interval 95%) months

From: Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study

Gene

Altered

Wild type

p

EGFR

36.5 (30.6–42.4)

28.4 (25.5–31.4)

< 0.0001

KRAS

24.4 (19.4–29.4)

32.5 (29.0–36.0)

0.0058

BRAF

32.5 (17.3–47.7)

30.7 (27.6–33.8)

0.7337

ALK

20.4 (12.8–27.9)

25.6 (22.2–28.9)

0.6493

MET

23.4 (10.2–36.6)

25.9 (22.2–29.5)

0.8454

EGFR

Males

33.9 (23.8–43.9)

26.4 (23.2–29.6)

0.0729

Females

36.7 (30.3–43.1)

31.9 (26.8–37.0)

0.0017

Smokers

33.1 (21.6–44.6)

26.4 (23.0–29.9)

0.1261

Never smokers

38.6 (30.3–46.8)

29.6 (20.6–38.6)

0.0275

KRAS

Males

23.4 (18.7–28.1)

29.1 (25.2–33.1)

0.3026

Females

24.2 (12.7–35.6)

36.5 (31.4–41.7)

0.0025

Smokers

24.0 (18.8–29.1)

27.8 (23.8–31.8)

0.4366

Never smokers

13.1 (6.7–19.4)

34.7 (27.8–41.5)

0.0055

  1. Statistically significant value is evidenced in bold